Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have earned an average recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $21.00.

ARTV has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 price target for the company.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $42,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Artiva Biotherapeutics by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after purchasing an additional 3,233 shares during the period. Wells Fargo & Company MN grew its stake in shares of Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares during the last quarter. Northern Trust Corp increased its holdings in Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after purchasing an additional 4,335 shares during the period. Finally, Barclays PLC raised its position in Artiva Biotherapeutics by 23.2% during the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock valued at $244,000 after purchasing an additional 4,545 shares during the last quarter.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ:ARTV opened at $3.77 on Tuesday. The company’s fifty day moving average price is $7.33 and its 200-day moving average price is $10.36. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.